Stock Track | Halozyme Soars 5% in Pre-Market on Raised 2025 Guidance and Share Buyback

Stock Track01-08 21:08

Halozyme Therapeutics (HALO) stock soared 5% in pre-market trading on Wednesday, outperforming the broader markets. The surge was driven by the company's improved financial guidance for 2025 and the announcement of a new share repurchase program.

In a press release, Halozyme reiterated its 2024 financial guidance, indicating that its business performance last year met expectations. However, the company raised its 2025 financial guidance, projecting robust growth across key metrics:

Total revenue is expected to grow 16-23% to $1.15-$1.23 billion, driven by increased royalty revenue and product sales.
Adjusted EBITDA is projected to grow 24-32% to $755-$805 million, reflecting strong profitability.
Non-GAAP diluted EPS is forecast to rise 21-30% to $4.95-$5.35, driven by top-line growth and operational efficiency.

Halozyme attributed the improved 2025 guidance to the strong performance of its products, including VYVGART, Darzalex SC, and Phesgo, as well as the recent launches of Ocrevus Zunovo, Tecentriq Hybreza, and Opdivo Qvantig. The company also announced a new $250 million accelerated share repurchase program, signaling its confidence in future growth prospects and commitment to enhancing shareholder value.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1198807458?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-08 21:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198807458","market":"hk","top_or_hot":-1,"title":"Stock Track | Halozyme Soars 5% in Pre-Market on Raised 2025 Guidance and Share Buyback","media":"Stock Track","content":"<p>Halozyme Therapeutics (HALO) stock soared 5% in pre-market trading on Wednesday, outperforming the broader markets. The surge was driven by the company's improved financial guidance for 2025 and the announcement of a new share repurchase program.</p>\n\n<p>In a press release, Halozyme reiterated its 2024 financial guidance, indicating that its business performance last year met expectations. However, the company raised its 2025 financial guidance, projecting robust growth across key metrics:</p>\n\n<ul>\n<li>Total revenue is expected to grow 16-23% to $1.15-$1.23 billion, driven by increased royalty revenue and product sales.</li>\n<li>Adjusted EBITDA is projected to grow 24-32% to $755-$805 million, reflecting strong profitability.</li>\n<li>Non-GAAP diluted EPS is forecast to rise 21-30% to $4.95-$5.35, driven by top-line growth and operational efficiency.</li>\n</ul>\n\n<p>Halozyme attributed the improved 2025 guidance to the strong performance of its products, including VYVGART, Darzalex SC, and Phesgo, as well as the recent launches of Ocrevus Zunovo, Tecentriq Hybreza, and Opdivo Qvantig. The company also announced a new $250 million accelerated share repurchase program, signaling its confidence in future growth prospects and commitment to enhancing shareholder value.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Halozyme Soars 5% in Pre-Market on Raised 2025 Guidance and Share Buyback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Halozyme Soars 5% in Pre-Market on Raised 2025 Guidance and Share Buyback\n</h2>\n\n<h4 class=\"meta\">\n\n2025-01-08 21:08 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Halozyme Therapeutics (HALO) stock soared 5% in pre-market trading on Wednesday, outperforming the broader markets. The surge was driven by the company's improved financial guidance for 2025 and the ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HALO","symbol_name":"奥洛兹美医疗","start_time":0,"source_url":"","article_id":"1198807458","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198807458","pubTimestamp":1736341701,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Halozyme Therapeutics  stock soared 5% in pre-market trading on Wednesday, outperforming the broader markets. The surge was driven by the company's improved financial guidance for 2025 and the announcement of a new share repurchase program.In a press release, Halozyme reiterated its 2024 financial guidance, indicating that its business performance last year met expectations. However, the company raised its 2025 financial guidance, projecting robust growth across key metrics:. Total revenue is ex","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HALO":"奥洛兹美医疗"},"translate_title":"股票赛道Halozyme因提高2025年指引和股票回购而盘前飙升5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HALO":1},"content_text":"Halozyme Therapeutics (HALO) stock soared 5% in pre-market trading on Wednesday, outperforming the broader markets. The surge was driven by the company's improved financial guidance for 2025 and the announcement of a new share repurchase program.\nIn a press release, Halozyme reiterated its 2024 financial guidance, indicating that its business performance last year met expectations. However, the company raised its 2025 financial guidance, projecting robust growth across key metrics:\n\nTotal revenue is expected to grow 16-23% to $1.15-$1.23 billion, driven by increased royalty revenue and product sales.\nAdjusted EBITDA is projected to grow 24-32% to $755-$805 million, reflecting strong profitability.\nNon-GAAP diluted EPS is forecast to rise 21-30% to $4.95-$5.35, driven by top-line growth and operational efficiency.\n\nHalozyme attributed the improved 2025 guidance to the strong performance of its products, including VYVGART, Darzalex SC, and Phesgo, as well as the recent launches of Ocrevus Zunovo, Tecentriq Hybreza, and Opdivo Qvantig. The company also announced a new $250 million accelerated share repurchase program, signaling its confidence in future growth prospects and commitment to enhancing shareholder value.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"buyback,movement","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1198807458"}